Literature DB >> 7688821

Mapping of B-neutralizing and T-helper cell epitopes on the bovine leukemia virus external glycoprotein gp51.

I Callebaut1, V Vonèche, A Mager, O Fumière, V Krchnak, M Merza, J Zavada, M Mammerickx, A Burny, D Portetelle.   

Abstract

A battery of 19 synthetic peptides was used to characterize efficient neutralizing and helper T-cell epitopes on the bovine leukemia virus (BLV) external envelope glycoprotein gp51. Four of the antipeptide antisera raised in rabbits inhibited the formation of BLV-induced syncytia; these antisera are directed against peptides 64-73, 98-117, and 177-192. Only antisera directed against the 177-192 region also neutralized vesicular stomatitis virus-BLV pseudotypes. This study clearly demonstrates that neutralizing properties can be observed with antibodies raised to regions undescribed so far and included in both the amino-terminal and central parts of the antigen. In addition, some helper T-cell determinants were defined from gp51-immunized mice and from BLV-infected cattle. Although none of the peptides tested behaved as a universal helper T-cell epitope, peptide 98-117 stimulated T-cell proliferation from BALB/c mice and from three infected cows, while peptide 169-188 strongly stimulated T-cell proliferation from one infected cow. Further experiments performed with three peptides overlapping the 169-188 region (177-192, 179-192, 181-192) demonstrated the particular relevance of residue(s) P-177 and/or D-178 in the helper T-cell epitope. These data should assist in the design of an efficient subunit vaccine against BLV infection that contains peptides possessing both B-neutralizing and helper T-cell determinants.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688821      PMCID: PMC237931     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Pseudotype particles of vesicular stomatitis virus with surface antigens of bovine leukaemia virus--VSV (BLV) -- as a sensitive probe for detecting antibodies in the sera of spontaneously infected cattle.

Authors:  J Závada; L Cerný; A D Altstein; Z Závadová
Journal:  Acta Virol       Date:  1978-03       Impact factor: 1.162

2.  Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70.

Authors:  M H Gatei; H M Naif; S Kumar; D B Boyle; R C Daniel; M F Good; M F Lavin
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

3.  Iodoacetamide treatment of bovine leukemia virus glycoprotein gp51 enhances the western blotting reactivity of anti-peptide antibodies.

Authors:  I Callebaut; A Burny; D Portetelle
Journal:  FEBS Lett       Date:  1991-11-04       Impact factor: 4.124

4.  Identification of T-helper epitopes in the VP1 capsid protein of poliovirus.

Authors:  M Kutubuddin; J Simons; M Chow
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

5.  Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.

Authors:  T J Palker; E R Riggs; D E Spragion; A J Muir; R M Scearce; R R Randall; M W McAdams; A McKnight; P R Clapham; R A Weiss
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

6.  Isolation and characterization of a 2.3-kilobase-pair cDNA fragment encoding the binding domain of the bovine leukemia virus cell receptor.

Authors:  J Ban; D Portetelle; C Altaner; B Horion; D Milan; V Krchnak; A Burny; R Kettmann
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

7.  In animals infected by bovine leukemia virus (BLV) antibodies to envelope glycoprotein gp51 are directed against the carbohydrate moiety.

Authors:  D Portetelle; C Bruck; M Mammerickx; A Burny
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

8.  Monoclonal antibodies define eight independent antigenic regions on the bovine leukemia virus (BLV) envelope glycoprotein gp51.

Authors:  C Bruck; S Mathot; D Portetelle; C Berte; J D Franssen; P Herion; A Burny
Journal:  Virology       Date:  1982-10-30       Impact factor: 3.616

9.  Simple, quantitative assay for both xenotropic murine leukemia and ecotropic feline leukemia viruses.

Authors:  P J Fischinger; C S Blevins; S Nomura
Journal:  J Virol       Date:  1974-07       Impact factor: 5.103

10.  Fusogenic segments of bovine leukemia virus and simian immunodeficiency virus are interchangeable and mediate fusion by means of oblique insertion in the lipid bilayer of their target cells.

Authors:  V Vonèche; D Portetelle; R Kettmann; L Willems; K Limbach; E Paoletti; J M Ruysschaert; A Burny; R Brasseur
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

View more
  23 in total

1.  Sequencing and phylogenetic analysis of gp51 gene of bovine leukaemia virus in Iranian isolates.

Authors:  F Hemmatzadeh
Journal:  Vet Res Commun       Date:  2007-02-08       Impact factor: 2.459

2.  Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and env-encoded BLV proteins.

Authors:  O Orlik; G A Splitter
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Genetic analysis of the pX region of bovine leukemia virus genotype 1 in Holstein Friesian cattle with different stages of infection.

Authors:  Neli Montero Machuca; Jorge Luis Tórtora Pérez; Ana Silvia González Méndez; Angélica Lucia García-Camacho; Ernesto Marín Flamand; Hugo Ramírez Álvarez
Journal:  Arch Virol       Date:  2021-10-14       Impact factor: 2.574

4.  Design and Synthesis of Bovine Leukemia Virus-Associated Peptide-Based Qβ Conjugate Eliciting Long-Lasting Neutralizing Antibodies in Mice.

Authors:  Shivangi Chugh; Cheryl Swenson; Vilma Yuzbasiyan-Gurkan; Xuefei Huang
Journal:  ACS Infect Dis       Date:  2022-04-28       Impact factor: 5.578

5.  Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo.

Authors:  Jean-Stéphane Gatot; Isabelle Callebaut; Carine Van Lint; Dominique Demonté; Pierre Kerkhofs; Daniel Portetelle; Arsène Burny; Luc Willems; Richard Kettmann
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

6.  Envelope proteins containing single amino acid substitutions support a structural model of the receptor-binding domain of bovine leukemia virus surface protein.

Authors:  Elizabeth R Johnston; Lorraine M Albritton; Kathryn Radke
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Characterization and modification of the carboxy-terminal sequences of bluetongue virus type 10 NS1 protein in relation to tubule formation and location of an antigenic epitope in the vicinity of the carboxy terminus of the protein.

Authors:  K Monastyrskaya; E A Gould; P Roy
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Identification and characterization of common B cell epitope in bovine leukemia virus via high-throughput peptide screening system in infected cattle.

Authors:  Lanlan Bai; Hiroyuki Otsuki; Hirotaka Sato; Junko Kohara; Emiko Isogai; Shin-nosuke Takeshima; Yoko Aida
Journal:  Retrovirology       Date:  2015-12-30       Impact factor: 4.602

9.  Agar gel immunodiffusion analysis using baculovirus-expressed recombinant bovine leukemia virus envelope glycoprotein (gp51/gp30(T-)).

Authors:  Seong In Lim; Wooseog Jeong; Dong Seob Tark; Dong Kun Yang; Chang Hee Kweon
Journal:  J Vet Sci       Date:  2009-12       Impact factor: 1.603

Review 10.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.